News
Scientists zero in on CD29 protein marker as key driver of MS
5+ hour, 35+ min ago (609+ words) Protein helps misguided immune cells reach the brain, triggers inflammation Written by Marisa Wexler, MS | April 6, 2026 In multiple sclerosis (MS), certain disease-driving immune cells carry a protein marker called CD29, which helps them move into the brain and trigger inflammation. That…...
New model of nerve fibers could speed path for MS treatments
4+ day, 4+ hour ago (694+ words) Soft, flexible platform designed to test myelin repair Written by Marisa Wexler, MS | April 2, 2026 A new model of nerve fibers aims to more closely replicate human axons. (Image from iStock) A new soft, flexible nerve fiber model helps screen MS…...
Gut cells prime T-cells to trigger brain inflammation in MS: Study
5+ day, 6+ hour ago (490+ words) Results point to gut as potential target site for therapies Written by Marisa Wexler, MS | April 1, 2026 An image shows the intestinal cells lining the gut. (Image from iStock) The cells that line the inside of the gut " known as intestinal…...
Quantum soon to seek FDA OK for trial testing Lucid-MS in patients
1+ week, 7+ hour ago (508+ words) Quantum names principal investigator, to soon seek FDA OK to launch study Written by Michela Luciano, PhD | March 30, 2026 Quantum Biopharma is preparing to seek permission in the U.S. to launch its planned clinical trial of Lucid-MS, an oral therapy that aims…...
Variations in protein could drive faster progress in some MS types
1+ week, 4+ day ago (598+ words) Study: Targeting it could boost myelin repair, opening new therapeutic avenues Written by Marisa Wexler, MS | March 26, 2026 A 3D rendering shows a large number of human brains within a circle. Variations in p21 protein activity may cause poor myelin repair in multiple…...
MS therapy CDR111 advances after meeting preclinical milestone
1+ week, 5+ day ago (441+ words) Written by Andrea Lobo, PhD | March 25, 2026 A 3d rendering shows antibodies. CDR111, an experimental therapy for MS, targets harmful B-cells driving inflammation. It works by engaging T-cells to destroy B-cells, aiming for broad B-cell depletion. Preclinical studies in cells and animals support…...
New MS immunotherapy IMP761 found safe, well tolerated in trial
1+ week, 5+ day ago (486+ words) Written by Andrea Lobo, PhD | March 25, 2026 IMP761, an experimental immunosuppressive therapy being developed by Immutep for multiple sclerosis (MS) and other autoimmune diseases, was well tolerated in healthy volunteers when given at single increasing doses. The findings come from the single-ascending…...
Close relatives of MS patients at higher risk of developing disorder
2+ week, 4+ day ago (706+ words) Study findings support feasibility of trials aimed at preventing disease Written by Steve Bryson, PhD | March 19, 2026 Close relatives of people with multiple sclerosis (MS) are 100 times more likely to develop the neurological disorder than the general population, according to a…...
Briumvi outperforms Aubagio in highly active relapsing MS: Study
3+ week, 5+ day ago (763+ words) Infusion therapy better at reducing disease activity on brain MRI scans Written by Margarida Maia, PhD | March 11, 2026 A doctor holds up an MRI brain scan of the head and skull. The CD20 inhibitor Briumvi (ublituximab) significantly outperformed Aubagio (teriflunomide) at lowering…...
Late-onset MS linked to faster disability progression: Study
2+ week, 5+ day ago (643+ words) Those whose symptoms start after age 50 also more commonly develop PPMS Written by Andrea Lobo, PhD | March 18, 2026 Late-onset MS (after age 50) is linked to faster disability progression. Late-onset MS patients more commonly develop primary progressive MS. Further research is needed…...